STOCK TITAN

Livanova Plc - LIVN STOCK NEWS

Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.

LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.

Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.

Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.

Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.

Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) has received FDA approval to launch the OSPREY clinical study for its aura6000® System, aimed at treating moderate to severe obstructive sleep apnea (OSA). This system provides a less restrictive alternative to CPAP machines by using an implantable pulse generator to stimulate the hypoglossal nerve, helping keep airways open during sleep. The randomized controlled trial will take place at about 20 sites across the U.S. and enroll up to 150 patients. OSA affects roughly one billion people globally, creating a significant market opportunity for innovative treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) has completed the initial closing of its heart valve (HV) business divestiture to Gyrus Capital for €60 million (approx. $73 million). This strategic move allows LivaNova to concentrate on its core cardiovascular and neuromodulation markets. The HV business, expected to generate $70 million in net revenues, will transition 850 employees to Gyrus's newly formed company, CORCYM. Post-divestiture, LivaNova anticipates full-year adjusted EPS between $1.31 to $1.81, reflecting a dilution of approximately $0.09 due to the sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will present at the UBS Global Healthcare Virtual Conference on May 25 at 8 a.m. ET. This presentation is accessible to the public via a live webcast on the LivaNova website. Interested listeners are advised to log in 10 minutes early for setup. The webcast will be available for replay for 30 days following the event. LivaNova, headquartered in London, is a leading medical technology company dedicated to improving patient lives globally with a workforce of approximately 4,000 employees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
conferences
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) reported a 2.1% increase in worldwide sales for Q1 2021, totaling $247.6 million, but a decline of 0.4% on a constant-currency basis. The company experienced a diluted loss per share of $0.61 under GAAP, while adjusted diluted EPS was $0.35, up from $0.33 in Q1 2020. Notably, Neuromodulation sales rose by 15.7%, while Cardiovascular sales fell by 9.4%. For 2021, LivaNova anticipates net sales growth between 8% and 13%, reaffirming its full-year guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) announced the randomization of the 300th patient in its ANTHEM-HFrEF Pivotal Study, aiming to evaluate Autonomic Regulation Therapy (ART) for heart failure treatment. This FDA-approved study will analyze the effectiveness of Vagus Nerve Stimulation (VNS) on symptoms and clinical outcomes in heart failure patients with reduced ejection fraction. The VITARIA System, designed for ART delivery, may become a first-in-class device if approved. Notable clinical outcomes include symptom relief and reduced hospitalizations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will host a conference call on April 28, 2021, at 12 p.m. London time (7 a.m. EDT) to discuss its Q1 2021 results. The results will be released prior to the call. Interested listeners can access a live audiocast via the Investors section of LivaNova's website. The dial-in numbers include 844-558-0159 for U.S. and Canada and 236-714-3182 for other regions, with a conference ID of 6493742. A replay will be available for 90 days following the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) reported a Q4 2020 revenue of $269.6 million, a 6.3% decline compared to Q4 2019, impacted by COVID-19. The diluted loss per share was $5.74, while adjusted EPS was $0.71. Cardiovascular sales fell by 10.1%, with Heart Valves down 27.2%, but Advanced Circulatory Support saw a 50.3% increase. For FY 2020, total sales decreased by 13.8% to $934.2 million. Looking ahead, LivaNova forecasts 2021 sales growth of 8-13% and adjusted EPS between $1.40 and $1.90, despite ongoing COVID-related uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) will hold a conference call on February 24, 2021, at 1 p.m. London time (8 a.m. EST) to discuss its fourth quarter and full-year 2020 results, which will be released prior to the call. Interested parties can access a live audiocast on LivaNova's Investor Relations website. For phone access, dial 844-239-5285 or 512-961-6524, using conference ID 1290829. A replay will be available for 90 days post-call. LivaNova is a global medical technology company dedicated to innovative healthcare solutions, serving over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
Rhea-AI Summary

LivaNova PLC (NASDAQ:LIVN) will host a virtual symposium titled "Updates and Advances in Neuromodulation" at AES2020 on December 6, 2020, from 6 to 8:30 p.m. ET. The event will feature leading clinicians discussing the role of VNS Therapy in treating drug-resistant epilepsy (DRE) and other disorders. Attendees will explore the economic and healthcare burdens of DRE and learn how VNS Therapy can alleviate these challenges. The symposium is free for AES2020 registrants, and a recording will be available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
Livanova Plc

Nasdaq:LIVN

LIVN Rankings

LIVN Stock Data

1.85B
54.14M
0.33%
104.41%
2.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United Kingdom
LONDON